Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.
暂无分享,去创建一个
P. Sonneveld | A. Waage | N. Abildgaard | E. Haukås | M. Hansson | M. Stevens-Kroef | M. Levin | S. Klein | S. Zweegman | F. Schjesvold | P. Poddighe | T. Do | B. Holt | N. Donk | D. Szatkowski | M. Leijs | E. V. D. Spek | C. Stege | P. Axelsson | Dorota Knut-Bojanovska | E. Spek | A. Svirskaite